Abstract:Supplementary Figure 1. Immunofluorescence and flow cytometry staining for EpCAM in leukemia and normal samples and leukemia cell lines. Supplementary Figure 2. Microarray analysis of markedly up-regulated genes in EpCAM-high cells relative to EpCAM-low cells. Supplementary Figure 3. EpCAM-high K562 cells are similar to tumor stem cells. Supplementary Figure 4. Analysis of AE7 specificity by flow cytometry and IHC/IF staining. Supplementary Figure 5. Analysis of the anti-tumor effect of EpCAM antibody in vivo (lung cancer, positive control) and in vitro. Supplementary Figure 6. Analysis of macrophage clearance after clodronate liposome injection by IF staining.

Supplementary Figure 3 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Figure 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Data from Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure S1 from Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody

Supplementary Figure 5 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figures from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Supplementary Figure 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 6 from BCMab1, A Monoclonal Antibody Against Aberrantly Glycosylated Integrin Α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>in Vivo</i>

Supplementary Table 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 2 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplementary Figure 3 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity Against Tumor Cells and Tumor Vasculature

Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>